Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

ASCO Connection

Effective May 2021, The Oncology Practice Insider newsletter consolidated with the ASCO Connection newsletter.

ASCO provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high-quality patient care, including updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. The biweekly ASCO Connection newsletter features the latest information on ASCO programs and resources for every member of the oncology community, including information tailored for practice administrators and practice leaders. Subscribe to the ASCO Connection newsletter for Practice News updates.

Over 7% of the U.S. population are Asian Americans, Native Hawaiians, and other Pacific Islanders. Uninsured rates vary among the different ethnicities in this group. The Centers for Medicare and Medicaid Services (CMS) is committed to policy and equity initiatives that help these communities find and use health care. During National Asian American, Native Hawaiian, and Pacific Islander Heritage Month, learn about the health needs of this population and find out how to reduce health disparities.
From April 4, 2022, through the end of the COVID-19 public health emergency, Medicare covers and pays for over-the-counter COVID-19 tests at no cost to patients. Under this new initiative, Medicare pays participating pharmacies and other health care providers directly. More Information can be found on the COVID-19 Over-the-Counter Tests webpage and find the list of participating providers.
On May 4, 2022, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy. Read more. 
The CMS Physicians, Nurses and Allied Health Professionals Open Door Forum (ODF) was held on Wednesday, April 27 from 2:00–3:00 PM (EDT). The call provided updates on the following:
On April 15, the Centers for Medicare and Medicaid Services (CMS) opened the Federal Independent Dispute Resolutions (IDR) portal. This process is for providers, facilities, and health plans and issuers to resolve payment disputes for certain out-of-network charges. To start a dispute, an initiating party will need the following:
The Centers for Medicare and Medicaid Services (CMS) recently posted updated Frequently Asked Questions (FAQs) for providers about the No Surprises rules. Visit the FAQs document for more information for providers and facilities regarding No Surprises rules, independent dispute resolution, and exceptions to the new rules and requirements.
On April 5, 2022, the Food and Drug Administration granted accelerated approval to alpelisib (Vijoice, Novartis Pharmaceuticals) for adult and pediatric patients two years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy. Read more.   
On March 23, 2022, the Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., a Novartis company) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.